AstraZeneca PLC (AZN)
| Market Cap | 282.01B +30.8% |
| Revenue (ttm) | 60.44B +9.9% |
| Net Income | 10.39B +33.7% |
| EPS | 6.64 +33.6% |
| Shares Out | 1.55B |
| PE Ratio | 27.15 |
| Forward PE | 17.16 |
| Dividend | $3.20 (1.75%) |
| Ex-Dividend Date | Feb 20, 2026 |
| Volume | 1,910,451 |
| Open | 182.71 |
| Previous Close | 182.52 |
| Day's Range | 181.58 - 183.55 |
| 52-Week Range | 131.03 - 212.71 |
| Beta | 0.22 |
| Analysts | Strong Buy |
| Price Target | n/a |
| Earnings Date | Apr 29, 2026 |
About AZN
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Crestor, Andexxa, Onglyza, Symlin, XIGDUO XR, Atacand, Atacand HCT, Atacand Plus, Farxiga/Forxiga, Plendil, Modip, Splendil, Munobal, Flodil, Tenormin, Tenormine, Prenormine, Atenol, Zestril, Brilinta/Brilique, Komboglyze, Qtern, Wainua, Byetta, Lokelma, Seloken ZOK, Topr... [Read more]
Financial Performance
In 2025, AstraZeneca's revenue was $58.74 billion, an increase of 8.63% compared to the previous year's $54.07 billion. Earnings were $10.23 billion, an increase of 45.34%.
Financial StatementsNews
IRW-News: ACCESS Newswire: AstraZeneca und OMP demonstrieren auf dem Gartner Supply Chain Symposium/Xpo(TM) 2 …
IRW-PRESS: ACCESS Newswire: AstraZeneca und OMP demonstrieren auf dem Gartner Supply Chain Symposium/Xpo(TM) 2026 Planung im Tempo des Wandels
CDT Equity announces AZD5904 progresses into patent cooperation treaty phase
CDT Equity (CDT) announced that AZD5904, a potent inhibitor of human Myeloperoxidase, originally licensed from AstraZeneca (AZN), has progressed into the patent cooperation treaty phase. A total of 18...
Ken Fisher's Strategic Moves: AstraZeneca PLC Leads the Portfolio Additions
Ken Fisher's Strategic Moves: AstraZeneca PLC Leads the Portfolio Additions
What does AstraZeneca's £300m investment mean for Cambridge?
Sir Kier Starmer announces the multi-million-pound investment in the House of Commons.
AstraZeneca Faces Setback as FDA Advisory Panel Rejects Cancer Drug (AZN)
AstraZeneca Faces Setback as FDA Advisory Panel Rejects Cancer Drug (AZN)
AstraZeneca Prostate Drug Wins FDA Panel Backing As Breast Cancer Candidate Falters
The U.S. Food and Drug Administration's Oncologic Drugs Advisory Committee (ODAC) delivered mixed recommendations for AstraZeneca Plc (NASDAQ:AZN), endorsing its prostate cancer regimen while declinin...
AstraZeneca stock falls after FDA panel votes against new cancer drug
An advisory panel for the U.S. Food and Drug Administration voted 6-3 against AstraZeneca's oral drug camizestrant intended for a type of breast cancer tumor, citing concerns around trial design. Astr...
ODAC recommends AstraZeneca Truqap for hormone-sensitive prostate cancer
The FDA Oncologic Drugs Advisory Committee, or ODAC, has recognized a favorable benefit risk profile for AstraZeneca’s (AZN) Truqap in combination with abiraterone and androgen deprivation therapy, or...
AstraZeneca: FDA Panel Recommends Truqap Combination For PTEN-Deficient Prostate Cancer
(RTTNews) - AstraZeneca (AZN) announced that the U.S. FDA's Oncologic Drugs Advisory Committee (ODAC) has recommended approval of Truqap in combination with abiraterone and androgen deprivation therap...
AstraZeneca's Breast-Cancer Candidate Drug Loses FDA Panel Vote
The British pharmaceutical group said it would continue to work with U.S. regulators on a review of its breast-cancer candidate after the drug failed to get backing at a key advisory committee vote.
AstraZeneca shares drop after US regulatory panel votes against breast cancer drug
Shares of AstraZeneca fell 1.7% on Friday after an advisory panel for the U.S. Food and Drug Administration overnight voted against recommending the British drugmaker's experimental breas...
AstraZeneca: Advisory Committee Recognises Favourable Benefit Risk Profile For Truqap Combination
LONDON (dpa-AFX) - AstraZeneca (AZN, AZN.L, ZEG.DE, AZN.ST) said the FDA's Oncologic Drugs Advisory Committee or ODAC has recognised a favourable benefit risk profile for AstraZeneca's Truqap in c...
TRUQAP (capivasertib) recommended by FDA Advisory Committee for PTEN-deficient metastatic hormone-sensitive prostate cancer
The US Food and Drug Administration’s (FDA) Oncologic Drugs Advisory Committee (ODAC) has recognized a favorable benefit risk profile for AstraZeneca’s TRUQAP (capivasertib) in combination with abirat...
AstraZeneca (AZN) Receives Positive FDA Advisory for Truqap in Prostate Cancer Treatment
AstraZeneca (AZN) Receives Positive FDA Advisory for Truqap in Prostate Cancer Treatment
AstraZeneca says FDA AdCom recommend Truqap in mHSPC
The company states: “The US Food and Drug Administration’s Oncologic Drugs Advisory Committee has recognised a favorable benefit risk profile for AstraZeneca’s (AZN) Truqap (capivasertib) in combinati...
AstraZeneca (AZN) Faces FDA Advisory Committee Vote on Camizestrant
AstraZeneca (AZN) Faces FDA Advisory Committee Vote on Camizestrant
AstraZeneca (AZN) Faces Setback, But Analyst Stays Bullish
AstraZeneca (AZN) Faces Setback, But Analyst Stays Bullish
AstraZeneca to ‘continue to work with FDA’ after vote against camizestrant
AstraZeneca (AZN) issued the following update on FDA advisory committee vote on camizestrant in combination with a cdk4/6 inhibitor for advanced hr-positive breast cancer: “The US Food and Drug Admini...
Jefferies says ODAC vote against AstraZeneca’s SERENA-6 not a surprise
Jefferies analyst Michael Leuchten maintained a Buy rating and $243 price target on AstraZeneca (AZN) following the FDA’s Oncologic Drugs Advisory Committee voting 6-3 against the recommendation of ca...
AstraZeneca (AZN) Faces Setback as FDA Panel Rejects Breast Cancer Drug
AstraZeneca (AZN) Faces Setback as FDA Panel Rejects Breast Cancer Drug
AstraZeneca (AZN) Faces Setback as FDA Advisory Panel Questions Drug's Benefit
AstraZeneca (AZN) Faces Setback as FDA Advisory Panel Questions Drug's Benefit
FDA panel votes 6-3 to reject AstraZeneca breast cancer drug, Bloomberg says
11:49 EDT FDA panel votes 6-3 to reject AstraZeneca (AZN) breast cancer drug, Bloomberg says Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try
Guardant falls after FDA panel votes down AstraZeneca breast cancer drug
Guardant Health (GH) shares are down 4% to $79.73 in midday trading. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See Insiders’
FDA panel votes against backing AstraZeneca's breast cancer drug
A panel of outside experts to the U.S. Food and Drug Administration voted against backing the risk-benefit profile of AstraZeneca's breast cancer drug, the company said on Thursday.
How AstraZeneca’s 17,000 AI-certified employees are helping it reach a ‘stretch goal’ of $80 billion in revenue
CFO Aradhana Sarin breaks down the building blocks behind the revenue target and reflects on a strong Q1.